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Circulating phagocytes during Azithromycin b'eatment of Cysfic 
Fibrosis patients with chronic Pseudomonas aeruginosa lung 
infection 
P.fJ. Jensen 1, C. Maser 1, T. Pressler 2, C. Koch 9., N. H0iby 1 
~Depart. of Clin. MicrobioI., 2The Copenhagen CF Centre, Rigstu~spitalet, 
Copenhagen, Det~nark 
Chronic Pseudomonas eruginosa lung infection is the major cause of early death 
ha Oystic Fibrosis (CF) patients. The infection is featured by/~ aeruginosa biofi lms 
surrounded by numerous PMNs in the lungs. The biofi lm growth increases the 
resistance of/~ aerugbu~sa to antibiotics and the host response. A beneficial effect 
of continued low dose macr olide treatment has recently been obtained in CF. 
To study it" macrolide treatment affects circulating phagocytes and the major 
cytokhaes for mobil izing phagocytes GM CSF and G CSF, 30 CF patients with 
chronic /~ aeruginosa lung infection were included. 20 patients had received 
250 mg Azithromycin daily for more than 3 months mad 10 patients continued 
without Azifl lr omycin treatment. Al l  patients were stable when investigated. These 
findings were compared to the same patients before Azithr omycin treatment. 
By FACS, an increased fraction of monceytes was seen ha the blood of both treated 
and untreated patients (P<0.05). The fraction of PMNs was unchanged. ELISA 
measurement s of serum samples howed a decreased concentration of G CSF in the 
treated patients (P<0.03) and no change of GM CSF ha both groups. 
We have previously sbown a cat,  elation between G CSF and poor lung function ha 
cbronically infected CF patients. Thus, the decreased G CSF concentration i the 
sera may be caused by anti hRlammat ory effects of Azitbr omycin. Surprisingly, the 
fraction of PMNs ha the blood was unchanged ha the treated group despite the 
decreased concentration of G CSF. This suggests that Azitbromycin increases the 
transit ime of PMNs in the blood by down~egulat ing of the cheroot actic activity ha 
the lungs resulting from an attenuation of the infection. 
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Aims: ha view of present difficulties ha monitoring the therapeutic benefit of 
treatments for Cystic Fibrosis (CF) there is a need for the development of new 
biomarker assays. Physiological measurements such as FEV 1 do not distinguish 
between established lung damage and active inflammation. We hypothesised that 
we would be able to detect disease specific biomarkers in induced sputum from 
adults with CF compared to both healthy control subjects and patients with other 
respiratory diseases. SELDI TOF mass spectromett3, was used to generate sputum 
protein profiles. 
Methods: Induced sputum was obtained from 28 patients with CF; 24 with Asthma; 
24 with COPD; 19 with non CF br onchiect asis and 24 healthy controls. Sputum was 
prceessed mad applied to a metal affinity SELDI TOF chip surface and protein 
profiles generated. Differential analysis of proteins was performed and p values 
calculated with Mama Whitney testing. 
Results: 79 biomar ker s differentiated CF from control (P<0.C~)I); 49 biomarkers CF 
from asthma (P<0.C~)I); 37 biomarkers CF from COPD (P<0.C~)I); and 4 
biomarkers CF from non CF bronchiectasis (P<0.C~)I). 
Conclusions: We have identified possible biomarkers of i lRlammation in induced 
sputum of patients with CF compared to control populations. The biomar ker profile 
of CF and non CF bronchiectasis are similar suggesting that these markers are 
specific to i lRlammation caused by bronchiectasis rather than CF per se. We did 
however discover 4 biomar ker s ha this study that are specific to CF when compared 
to br onchiect asis. Protein identification work is ongoing. Further validation of these 
markers ha longitudinal studies is required. 
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Efficiency of sputum processing for inflammatory cell counts in 
cystic fibrosis 
A. Etthimiadis, R. Labiris, L. Jayar am, A. Freitag, F.E. Hargreave 
St. Joseph's Healthcare a~u] McMaster University, Hamilton, Ontario Canada 
Aim: To examine the efficiency, reliabil ity and validity of pr ccessing spontaneously 
expectorated sputum in cystic fibrosis (CF). 
Methods: Sputum was collected from 35 adults with CF and compared with sputum 
from 16 adults with infective bronchitis or bronchiectasis (IB/B) or from 25 adults 
with asthma or chronic obstructive pulmonary disease (AS/COPD). Within 2 hours, 
a small portion (100 to 2CO rag) of sputum was selected and prccessed with four 
volumes of dithiothreitol (0.1%) followed by four volumes of phosphate buffered 
saline and fi ltered through a 48 ~tm nylon mesh. The total cell count (TCC) and 
viability (V) were obtained ha a Neubauer chamber and cyt ospins were prepared mad 
stained with Wright's for a 400 non squamous cell differential. Efficiency of 
dispersal was determined by comparing the mean loss in cell yield to the filter, 
reliabil ity (R) by comparing cell counts ha two different portions from the same 
sample and validity by comparing cell counts ha CF to those in IB/B and AS/COPD. 
Results: The mean loss in total cell yield to the filter was similar ha CF, IB/B and 
AS/COPD; (5.3 vs. 8.6 vs. 7.5%) and was non selective. 
TC'Cx 10~/g V go Neut go Eos go 
No* real 44 (48) 37 5 (201) 04 (09) 
CF 467 (391) 800 (210) 963 (37) 03 (05 
R 096 097 080 087 
II3113 612 (788) 870 (95) 924 (7 0) 03 (06) 
R 099 098 095 094 
AS/COPD 34 (5 0) 610 (490) 547 (320) 58 (140) 
R 097 097 097 096 
*Normal values from Belda t a l AIRCCM 2000; 161:475 478 
Reliabil ity of cell counts between the 2 portions from the same sputum sample was 
excellent, >0.8 in all groups. Sputum from CF and IB/B had similar mediml total 
cell counts, proportion of viable cells, neutrophils and eosinophils. Sputum from 
CF, in comparison to AS/COPD, had a higher mediml total cell count, proportion of 
viable cells, and a lower proportion of eosinopbils. 
Conclusion: Sputum examination provides a method to study hRlammation in 
airway diseases. When a small  volume of CF sputum is examined as described mid 
the sputum is efficiently pr ceessed, it yields reliable and valid cell counts. 
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Laboratory and clinical effect of long-term roxithromycin treatment in 
adult patients with cysfic fibrosis 
V. Dionyssopoulou, G. Perpati, E. Stefanatou, E. Cbristodoulou, E. Kalatzi, E. 
Armeniakou, E. Karimlou, E. Pappa, A. Papamichalopoulos, E. Pouliou 
Cystic Fibrosis ou~vatient clinic. Athens Chest Hospital, Greece 
Introduction: Viscious cycle inf lammation i fection play an important role in 
pathogenesis of cystic fibrosis (CF). There is a growing interest in the potential use 
of macrolide antibiotics as anti hfflammatory agents in CF. 
Aim: The aim of this study was to determine the effect of r oxithromycin on ilfflam 
mation, lung function and duration of hospitalization i adult patients with CF. 
Methods: Twenty f ive patients (12 male and 13 female, aged 26 + 9) on stable state 
were investigated ha a randomized controlled trial. Fifteen of them (6 male mad 9 
female, aged 24 + 5) had a mean change o fFEV 1 8.4% per year and 25.6 days of 
hospitalization for the last year. Ten patients (6 male mad 4 female, aged 29 + 13) 
had a mean change of FEV 1 5.2% and 27.3 days of hospitalization for the last year. 
In patients of both groups IL 113, IL  6, IL  8 and TNFo: were measured with high 
sensitivity EL ISA method. Patients of the first group were  treated w i th  
roxithromycin 150 mg/d for e ighteen months. After that, measurement of 
ilfflammatory cyt okhaes has been repeated ha patients of both groups. 
Results: Levels of i lfflammatory markers were decreased significantly ha patients 
treated with roxithr omycin compared to patients not treated with macr olide (IL 113: 
1.06 pg/ml to 0.28 vs 1.36 to 1.68, P<0.010. IL 6 :3 .6  pg/ml to 0.4 vs 2.54 to 2.94, 
P<0.CO5. IL  8:5.1 pg/ml to 1.26 vs 4.75 to 4.58, P<0.002. TNFa: 2.9 pg/ml to 1.28 
vs 2.5 to 3 .02,  P<0.CO5). Change ha FEV1 was 2.5% per year in patients treated 
with roxithr omycin vs 5 % (P<0.02). Also, the days of hospitalization l imited ha 17 
per year ha comparison to patients no treated (27.4 d, P<0.03). 
CotwIusion: Low dose long term administration of roxithromycin i  adult patients 
with CF reduces il lf lammation, improve lung function and l imits duration of 
hospitalization. 
